| Document |
Document Title |
|
JP3295426B2 |
Novel antihypercholesterolemic agents are provided. An exemplary group of compounds has the structural formula (I) (I) wherein R is a C-17 side chain, R1 is -OH, =O, or the like, and X and Y are CH, C-OH, C-OCH3 or C-Z. Methods of using ...
|
|
JP3292928B2 |
The present invention relates to compounds of the formula: in which X1 and X2 correspond to H or F without distinction; R1 represents the following radicals: and R2 represents the radicals in the form of an R epimer, an S epimer, or a st...
|
|
JP2002155097A |
To convert a 6β-fluorosteroid into a corresponding pharmacologically active 6α-fluoro derivative without requiring vigorous reaction conditions.This method for isomerizing a 6β-fluoro derivative into a corresponding 6α-fluoro derivat...
|
|
JP3279574B2 |
A pharmaceutical composition for treating a hepatic disorder, comprising a triterpene derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof is disclosed: wherein R<1> represents a hydroxyl group, alkoxy,...
|
|
JP3273010B2 |
To obtain a compound useful for treating a disease corresponding to a sex steroid. This sex steroid inhibitor has a molecular structure of formula I (a dotted line is a double bond; R5 and R6 are each H, hydroxyl, etc.; R100 is a divalen...
|
|
JP2002060384A |
To obtain a compound useful for treating breast cancer or other diseases promoted by their exacerbation due to the activation of sex steroid receptor, and to provide a medicament composition containing the above compound.This compound ha...
|
|
JP2002030063A |
To provide a method for producing a sulfamate compound, which can be applied to various hydroxyl group-containing compounds having various functional groups and by which the sulfamate compound can be produced from necessary minimal amoun...
|
|
JP2002500190A |
This invention provides novel compounds derived from a marine sponge, Adocia sp., that specifically modulat kinesin activity by targeting the kinesin motor domain and mimicking the activity a microtubule. The compounds act as potent anti...
|
|
JP2001526685A |
A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula in which: R1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R2 is acetyl or isobutanoyl, in particular ci...
|
|
JP2001525333A |
(57) [Summary] 16α, 17α-dialkylated steroids are prepared by reacting 16α-alkyl-17 (20) -enyl-20-silyl ether with an alkylating agent and an enol silyl ether cleavage agent in a suitable solvent. It was.
|
|
JP2001523638A5 |
|
|
JP2001523259A |
4-Aza-steroid compounds are provided, which have functional groups at one or more of positions 7, 11 and 15, such as hydroxyl or hydroxyl derivative groups. The compounds are active against 5-alpha-reductase giving indications of utility...
|
|
JP2001515518A |
PCT No. PCT/EP98/08527 Sec. 371 Date Aug. 27, 1999 Sec. 102(e) Date Aug. 27, 1999 PCT Filed Dec. 17, 1998 PCT Pub. No. WO99/35161 PCT Pub. Date Jul. 15, 1999A process for producing a compound of formula (I): wherein the dotted lines - - ...
|
|
JP3205389B2 |
PURPOSE: To provide the new steroids having specific aromatase-inhibitory properties. CONSTITUTION: The steroids are compounds represented by the formula I (wherein: R is a substituent such as 1-4C alkyl or alkenyl group; Y is O or a res...
|
|
JP3202229B2 |
PCT No. PCT/EP91/02239 Sec. 371 Date Sep. 28, 1993 Sec. 102(e) Date Sep. 28, 1993 PCT Filed Nov. 27, 1991 PCT Pub. No. WO92/09618 PCT Pub. Date Jun. 11, 1992.8-En-19,11 beta -bridged steroids of general formula I (I) that have the 8,9-do...
|
|
JP2001509792A |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula Iwherein-A-A- represents the group -CHR4-CHR5- or -CR4=CR5-;R3, R4 and R5 are in...
|
|
JP3181589B2 |
PCT No. PCT/EP91/02493 Sec. 371 Date Oct. 27, 1993 Sec. 102(e) Date Oct. 27, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11277 PCT Pub. Date Jul. 9, 1992Compounds of the general formula I (I) are described, in which x represents an ox...
|
|
JP2001181296A |
To provide a new substance having antimycotic action. The objective substance is a steroid saponin expressed by formula.
|
|
JP3179495B2 |
1 alpha ,24(S)-Dihydroxy vitamin D2 which is useful as an active compound of pharmaceutical compositions for the treatment of disorders of calcium metabolism and for various skin disorders. The invention also includes preparation of synt...
|
|
JP2001508079A |
PCT No. PCT/EP98/00377 Sec. 371 Date Jul. 14, 1999 Sec. 102(e) Date Jul. 14, 1999 PCT Filed Jan. 13, 1998 PCT Pub. No. WO98/31702 PCT Pub. Date Jul. 23, 1998The present invention relates to certain 16-hydroxy-11-(substituted phenyl)-estr...
|
|
JP3172575B2 |
PURPOSE: To provide a compd. useful for production of a budesonide and desonide. CONSTITUTION: The compd. of formula I (R is H, a 1 to 8C acyl, etc.). For example, (11β.16α)-21-(acetyloxy)-11-(formyloxy-16,17-[(1-methyleth
ylidene)bis(...
|
|
JP3168542B2 |
The invention is directed to the control of cellular autophagy, cellular agglutination and the immobilization of motile cells. Such control is useful in, for example, the treatment of cancer, contraception, termination of pregnancy, remo...
|
|
JP3165576B2 |
PURPOSE: To obtain the subject compound useful as a synthetic intermediate for vitamin D derivatives having physiological activity such as in vivo Ca regulating action in high yield by reacting a specific epoxy compound with alcohols und...
|
|
JP2001503732A |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
JP2001019618A |
To obtain a bleaching agent having melanin suppressing actions and tyrosinase activity suppressing actions and excellent in lightening and bleaching effects on pigmentation, dermal stains, ephelides and chloasmata after sunburn by using ...
|
|
JP3123745B2 |
|
|
JP2001002698A |
To obtain a new compound excellent in safety, having new mechanism of action and useful as a anticancer agent.This compound is represented by the formula. The compound of the formula is obtained by extracting e.g. a plant of the family L...
|
|
JP2000351798A |
To obtain a steroid compound useful as an intermediate for producing various kinds of vitamin D derivatives useful for the therapy of chronic renal failure, hypoparathyroidism, etc., by the solvolysis of the enol ester part of a specific...
|
|
JP2000351795A |
To obtain a steroid derivative as an intermediate for producing various kinds of vitamin D derivatives useful for the therapy of chronic renal failure, hypoparathyroidism, etc., by way of a process where a palladium compound is made to a...
|
|
JP2000351797A |
To obtain a steroid compound useful as an intermediate for producing various kinds of vitamin D derivatives useful for the therapy of chronic renal failure, hypoparathyroidism, etc., by epoxidizing a specific diene compound.A 1,2-epoxy-5...
|
|
JP2000351796A |
To obtain a steroid compound useful as an intermediate for producing various kinds of vitamin D derivatives useful for the therapy of chronic renal failure, hypoparathyroidism, etc., by oxidizing a specific steroid compound.A 1,2-epoxy c...
|
|
JP2000516625A |
(57) [Summary] The present invention relates to a method for producing eltanorone (I), which is characterized by using epi-salsa sapogenin (II) with acetic anhydride in the presence of ammonium chloride and pyridine, 3α, 26-diacetoxy-. ...
|
|
JP2000515163A |
(57) [Summary] General formula (I) (in formula, R1Represents a hydrogen atom, an alkyl group with a maximum of 4 carbon atoms, a benzyl group or an acyl group with a maximum of 8 carbon atoms, and X and Y together represent an oxo group,...
|
|
JP2000513380A |
There are described therapeutically active compounds or salts or solvates thereof, hydrolysable in human or animal blood to compounds with reduced therapeutic activity. There is also described a method of identifying a compound capable o...
|
|
JP2000273099A |
To produce the subject derivative having a halogen atom at a specific position, capable of allowing various side chains to be introduced by utilizing the reactivity of the halogen atom, capable of allowing a protection step and a deprote...
|
|
JP2000256391A |
To obtain a new saponin having an inhibitory action on acylcoenzyme A cholesterol acyltransferase(ACAT) activity, useful for prevention, therapy, or the like, of arteriosclerosis. This compound is expressed by formula I (R1-R7 are each a...
|
|
JP2000256390A |
To obtain a medicine composition useful for treating diseases related to estrogen and androgen by making the composition include a pharmacologically acceptable diluent, or the like, and a specific sex steroid activity inhibitor. This com...
|
|
JP2000256392A |
To obtain an ACAT inhibitor having ACAT inhibiting action useful for prevention and therapy of arteriosclerosis such as atherosclerosis, or the like, by including a specific triterpene. The inhibitor comprises triterpentine compounds of ...
|
|
JP2000239296A |
To obtain a new cytostatic agent which reduces the problems of the side effects and tolerance of carcinostatic agents conventionally used for cancer chemotherapy. This cytostatic agent is obtained by finding that the ingredients derived ...
|
|
JP2000204043A |
To obtain the subject inhibitor useful for prophylatic and treating morbid states and diseases caused by active oxygen such as arteriosclerosis, cerebral infarction, ulcer, malignant tumor or diabetes by including a specific saponin comp...
|
|
JP2000509016A |
Disclosed are (i) compounds of a steroid, a beta-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous produc...
|
|
JP2000509072A |
The present invention relates to a pharmaceutical composition or preparation which comprises hydroxyl containing steroidal hormones and organic nitrite/nitrate or other nitric oxide donating agents.
|
|
JP3049504B2 |
Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatlc steroids and their use in treating ocular hypertension, including controlling the ocular hypertension associate...
|
|
JP2000136130A |
To obtain the subject suppressant by including alnusenol and multiflorenol as active ingredients. This suppressant is obtained by including alnusenol represented by formula I and/or multiflorenol represented by formula II as active ingre...
|
|
JP2000128897A |
To obtain the subject high-purity compound without requiring a high- cost time-consuming purification process by stereoselectively subjecting a specific budesonide derivative to transketalization with butyraldehyde in the presence of a s...
|
|
JP2000119297A |
To obtain a new substance available from a sponge belonging to the genus Lendenfeldia, having an attachment inhibiting activity for marine fouling organisms and useful as an antifouling agent for the marine fouling organisms.This compoun...
|
|
JP3037427B2 |
Starting compounds for preparing calcitriol (1$g(a), 25-dihydroxycholecalciferol) and its derivatives showing, as compared with calcitriol, some modifications, particularly in the C-17 lateral chain, a method for preparing these starting...
|
|
JP3031585B2 |
PURPOSE: To obtain a lyase enzyme inhibitor which contains specific aminosteroids and is useful as a treating agent for androgen and estrogen dependent diseases, such as prostatic cancers and prostatic hypertrophies. CONSTITUTION: This 1...
|
|
JP2000504025A |
The invention relates to a method of altering the blood levels of LH or FSH in an individual. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithel...
|
|
JP3021651B2 |
The present invention is directed to 2 beta ,19-(methyleneamino)androst-4-ene-3,17-dione which has the formula and the corresponding 17 beta -ol which are useful as aromatase inhibitors. The compounds are prepared by the cyclization of a...
|
